OC
SGMO

Oppenheimer & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Oppenheimer & Co’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-47,000
Closed -$230K – 1421
2022
Q3 		$230K Sell
47,000
-29,600
-39% -$152K 0.01% 1166
2022
Q2 		$317K Sell
76,600
-41,850
-35% -$181K 0.01% 1090
2022
Q1 		$688K Hold
118,450
– – 0.01% 888
2021
Q4 		$888K Sell
118,450
-36,850
-24% -$320K 0.02% 819
2021
Q3 		$1.4M Sell
155,300
-41,563
-21% -$411K 0.03% 620
2021
Q2 		$2.36M Buy
196,863
+130,300
+196% +$1.48M 0.04% 466
2021
Q1 		$834K Buy
+66,563
New +$897K 0.02% 767

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oppenheimer & Co's SGMO Position: Q4 2022 in Review

Oppenheimer & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2022, closing a stake of 47,000 shares — an estimated $230K sold.

Oppenheimer & Co first reported a position in SGMO in Q1 2021 and held it in 7 quarters. The position peaked at $2.36M in Q2 2021. 182 funds tracked by Wall St. Rank hold SGMO as of Q4 2022.

  • Oppenheimer & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 47,000 SANGAMO THERAPEUTICS INC shares in Q4 2022, an estimated $230K.
  • Oppenheimer & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 7 quarters.
  • Oppenheimer & Co's SANGAMO THERAPEUTICS INC position peaked at $2.36M in Q2 2021.
  • 182 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2022.

Based on Oppenheimer & Co's 13F filing for Q4 2022, filed 8 Feb 2023.